Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Datopotamab Deruxtecan + Durvalumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Datopotamab Deruxtecan||Dato-DXd|DS1062a|DS 1062a|DS-1062a||Datopotamab Deruxtecan (DS-1062a) is an antibody-drug conjugate comprising an antibody that targets TROP2 linked to the topoisomerase I inhibitor DXd, which may induce apoptosis and inhibit tumor growth (PMID: 34413126).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04612751||Phase I||Datopotamab Deruxtecan + Durvalumab||Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab With or Without Carboplatin in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)||Recruiting||USA | FRA||1|